A comparison of concurrent chemoradiotherapy and radiotherapy in Chinese patients with locally advanced cervical carcinoma: A multi-center study

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Li, Zhijie ^a   Yang, Shuyan ^a   Liu, Lei ^a   Han, Shiyu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Advanced cervical carcinoma; Concurrent chemoradiation; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84924233367     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-212     Document Type: Article

References (36)

1. Maduro JH, Pras E, Willemse PH, de Vries EG: Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 2003, 29:471–488.
2. Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ: A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003, 68:217–226.
3. Denton AS, Bond SJ, Matthews S, Bentzen SM, Maher EJ, UK Link Gynaecology-Oncology Group: National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993. Clin Oncol (R Coll Radiol) 2000, 12:347–353.
4. Lajer H, Thranov IR, Skovgaard LT, Engelholm SA: Late urologic morbidity in 177 consecutive patients after radiotherapy for cervical carcinoma: a longitudinal study. Int J Radiat Oncol Biol Phys 2002, 54:1356–1361.
5. National Cancer Institutes: Guidelines gynaecologic tumours: cervical carcinoma [Internet]. Bethesda, MD: National Cancer Instututes; 2004. [cited 2011 Jun 20]. Available from: http://www.cancer.gov.
6. Thomas GM: Improved treatment for cervical cancer: concurrent chemotherapy and radiotherapy. N Engl J Med 1999, 340:1198–1200.
7. King M, McConkey C, Latief TN, Hartley A, Fernando I: Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol) 2006, 18:38–45.
8. Einarsson JI, Cohen SL, Puntambekar S: Orifice-assisted small-incision surgery: case series in benign and oncologic gynecology. J Minim Invasive Gynecol 2012, 19(3):365–368.
9. Höckel M, Horn LC, Einenkel J: (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of theuterine cervix and vagina based on ontogenetic anatomy. Gynecol Oncol 2012, 127(2):297–302.
10. Liu SP, Huang X, Ke GH, Huang XW: 3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervicalcancer: the Shanghai Cancer Hospital experience. PLoS One 2012, 7(6):e40299.
11. Forrest J, Presutti J, Davidson M, Hamilton P, Kiss A, Thomas G: A dosimetric planning study comparing intensity-modulated radiotherapy with four-field conformal pelvic radiotherapy for the definitive treatment of cervical carcinoma. Clin Oncol (R Coll Radiol) 2012, 24(4):e63–e70.
12. Muderspach LI, Curtin JP, Roman LD, Gebhardt JA, Klement V, Qian D, Morrow CP, Felix JC, Formenti SC, Muggia FM: Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study. Gynecol Oncol 1997, 65(2):336–342.
13. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD: A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cellcarcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989, 32(2):198–202.
14. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R, Kavanagh JJ: An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997, 8(7):657–661.
15. Puls LE, Phillips B, Schammel C, Hunter JE, Griffin D: A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma. Med Oncol 2010, 27(2):368–372.
16. Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS: Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol 2000, 76(2):204–207.
17. Vallejo CT, Machiavelli MR, Pérez JE, Romero AO, Bologna F, Vicente H, Lacava JA, Ortiz EH, Cubero A, Focaccia G, Suttora G, Scenna M, Boughen JM, Leone BA: Docetaxel as neoadjuvant chemotherapy in patients with advanced cervical carcinoma. Am J Clin Oncol 2003, 26(5):477–482.
18. Buxton EJ, Blackledge G, Mould JJ, Monaghan J, Paterson M, Tobias J, Alcock C, Spooner D, Meanwell CA: The role of ifosfamide in cervical cancer. Semin Oncol 1989, 16(1 Suppl 3):60–67.
19. Colombo A, Landoni F, Cormio G, Barni S, Maneo A, Nava S, Pellegrino A, Placa F, Mangioni C: Concurrent carboplatin/5FU and radiotherapy compared to radiotherapy alone in locally advanced cervical carcinoma: a case-control study. Tumori 1997, 83(6):895–899.
20. Irvin WP, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ, Potkul RK: A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer 1998, 82(2):328–333.
21. Thigpen T, Blessing JA, Gallup DG, Maiman M, Soper JT: Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1995, 57(3):376–379.
22. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014, 370(8):734–743.
23. van der Zee J, González González D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA: Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000, 355(9210):1119–1125.
24. Schefter TE, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, Small W Jr, Gaffney DK: A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys 2012, 83(4):1179–1184.
25. Giorda G, Boz G, Gadducci A, Lucia E, De Piero G, De Paoli A, Innocente R, Trovò M, Sorio R, Campagnutta E: Multimodality approach in extra cervical locally advanced cervical cancer: chemoradiation, surgery and intra-operative radiation therapy: A phase II trial. Eur J Surg Oncol 2011, 37(5):442–447.
26. Chassagne D, Sismondi P, Horiot JC, Sinistrero G, Bey P, Zola P, Pernot M, Gerbaulet A, Kunkler I, Michel G: A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol 1993, 26:195–202.
27. Ryu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, Choi SC, Cho CK, Nam BH, Lee ED: Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2011, 81(4):e577–e581.
28. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001, 358:781–786.
29. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration: Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008, 26:5802–5812.
30. Lukka H, Hirte H, Fyles A, Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M, Fung MF, Browman G, Cancer Care Ontario Practice Guidelines Initiative Gynecology Disease Site Group: Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer: a meta-analysis. Clin Oncol (R Coll Radiol) 2002, 14:203–212.
31. Tan LT, Russell S, Burgess L: Acute toxicity of chemo-radiotherapy for cervical cancer: the Addenbrooke’s experience. Clin Oncol (R Coll Radiol) 2004, 16:255–260.
32. Therasse P, Arbuck SG, Eisenhauer EA, Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216.
33. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0. 2006.
34. Coia L, Won M, Lanciano R, Marcial VA, Martz M, Hanks G: The patterns of care outcome study for cancer of the uterine cancer: Results of the second national practice survey. Cancer 1990, 66:2451–2456.
35. Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S, Gynecologic Oncology Group: Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:2804–2810.
36. Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B: Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol 2007, 107:310–315.